SCHEDULE 13G/A: AbbVie Biotechnology Reduces Stake in Carisma Therapeutics Below 5%
Beneficial Ownership Report
AbbVie Biotechnology Ltd. has filed an amended Schedule 13G, disclosing its beneficial ownership in Carisma Therapeutics Inc. has fallen to 4.4% of outstanding common stock.
Summary
- AbbVie Biotechnology Ltd. now beneficially owns 1,855,871 shares of Carisma Therapeutics Inc. common stock.
- This represents 4.4% of Carisma Therapeutics' common stock outstanding, calculated based on 41,788,096 shares as of March 26, 2025.
- AbbVie Biotechnology Ltd. holds shared voting and shared dispositive power over these shares.
- The filing is an Amendment No. 1 to a previous Schedule 13G, indicating a change in ownership from a prior report.
Sentiment
Score: 3
Explanation: The reduction of a significant stake by a major pharmaceutical company like AbbVie is generally viewed as a negative development for the issuer, Carisma Therapeutics, as it may signal reduced confidence or strategic alignment.
Negatives
- The reduction of AbbVie Biotechnology Ltd.'s stake to below 5% could be perceived as a negative signal by the market, suggesting a decreased strategic interest or confidence from a major pharmaceutical entity in Carisma Therapeutics Inc.
Future Outlook
NA
Industry Context
AbbVie Biotechnology Ltd. is an affiliate of AbbVie Inc., a global biopharmaceutical company. Their investment in Carisma Therapeutics, a biotechnology firm, previously indicated a potential strategic interest or partnership. The reduction of their stake below 5% suggests a shift in this relationship or investment strategy, which could impact market perception of Carisma Therapeutics within the competitive biotechnology landscape.
Stakeholder Impact
- Shareholders of Carisma Therapeutics Inc. may react negatively to the news of a significant investor like AbbVie Biotechnology Ltd. reducing its stake, potentially leading to downward pressure on the stock price.
Key Dates
| Date | Description |
|---|---|
| 2024-12-31 | Fiscal year end for Carisma Therapeutics Inc.'s annual report on Form 10-K. |
| 2025-03-26 | Date as of which 41,788,096 shares of Carisma Therapeutics Inc. Common Stock were outstanding, used for percentage calculation. |
| 2025-03-31 | Date of event which required the filing of this statement; also the filing date of Carisma Therapeutics Inc.'s annual report on Form 10-K. |
| 2025-04-25 | Date of signing and filing of this Schedule 13G Amendment No. 1 by AbbVie Biotechnology Ltd. |
Recommendation
sellKeywords
Carisma Therapeutics, AbbVie Biotechnology, Schedule 13G, beneficial ownership, common stock, biotechnology, pharmaceutical investment, stake reduction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.